EUVIMEDEUVIMED entdecken
Klinische Studie

Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study

Ainoa Ugarte iD, Lorena De La Mora, Elisa De Lazzari, Iván Chivite, Emma Fernández, Alexy Inciarte, Montserrat Laguno, Juan Ambrosioni, Estela Solbes, Leire Berrocal, Ana González-Cordón iD, María Martínez-Rebollar und 6 weitere

Journal of Antimicrobial Chemotherapy · 03.09.2024 · 79 (9) · 2343-2353

DOI: 10.1093/jac/dkae235 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 24.07.2024. Verfasst von Ainoa Ugarte und 17 weiteren Autor:innen. Beteiligte Einrichtung: HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona, Villarroel Street 170, Barcelona 08036, Spain. Hauptthemen laut MEDLINE: HIV Infections, Tenofovir, Emtricitabine, Anti-HIV Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Rapid initiation of ART after HIV diagnosis is recommended for individual and public health benefits. However, certain clinical and ART-related considerations hinder immediate initiation of therapy.

Methods

An open-label, single-arm, single-centre 48-week prospective clinical trial involving ART-naïve HIV-diagnosed adults who started bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) within a week from the first hospital visit, before the availability of baseline laboratory and genotype results. The primary aim was to determine the proportion of people with at least one condition that would hinder immediate initiation of any recommended ART regimen other than BIC/FTC/TAF. Clinicaltrials.gov: NCT04416906.

Results

We included 100 participants: 79% men, 64% from Latin America, median age 32 years. According to European AIDS Clinical Society (EACS) and US Department of Health and Human Services 2023 guidelines, 11% (95%CI 6; 19) of participants had at least one condition that made any ART different from BIC/FTC/TAF less appropriate for a rapid ART strategy. Seventy-nine percent of the people started BIC/FTC/TAF within the first 48 hours of their first hospital visit. There were 16 early discontinuations (11 lost to follow-up). By week 48, 92% (95%CI 86; 98) of the participants of the ITT population with observed data achieved viral suppression. Eight grade 3–4 adverse events (AEs), five serious AEs and six ART-related AEs were identified. Adherence remained high.

Conclusions

BIC/FTC/TAF is an optimal treatment for rapid initiation of ART. However, additional strategies to improve retention in care must be implemented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsTenofovirEmtricitabineAnti-HIV AgentsPyridonesAlanineHumansMaleAdultProspective StudiesFemaleHeterocyclic Compounds, 4 or More RingsPiperazinesAmidesAdenineDrug CombinationsHeterocyclic Compounds, 3-RingMiddle AgedYoung AdultViral Load

Substanzen

TenofovirEmtricitabineAnti-HIV AgentsPyridonesAlaninebictegravirHeterocyclic Compounds, 4 or More RingsPiperazinesAmidestenofovir alafenamide

Autor:innen und Institutionen

  • HIV Unit, Infectious Diseases Service, Hospital Clinic of Barcelona, Villarroel Street 170, Barcelona 08036, Spain.
  • University of Barcelona, Barcelona, Spain.
  • CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Carlos III, Madrid, Spain.

ORCID-Profile: Ainoa Ugarte, Ana González-Cordón, Esteban Martínez, Berta Torres

Förderung

  • Gilead Sciences

Zitieren

APA

Ugarte, A., De La Mora, L., De Lazzari, E., Chivite, I., Fernández, E., Inciarte, A., Laguno, M., Ambrosioni, J., Solbes, E., Berrocal, L., González-Cordón, A., Martínez-Rebollar, M., Foncillas, A., Calvo, J., Blanco, J. L., Martínez, E., Mallolas, J., & Torres, B. (2024). Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study. Journal of Antimicrobial Chemotherapy, 79(9), 2343-2353. https://doi.org/10.1093/jac/dkae235

Vancouver

Ugarte A, De La Mora L, De Lazzari E, Chivite I, Fernández E, Inciarte A, et al. Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study. Journal of Antimicrobial Chemotherapy. 2024;79(9):2343-2353. doi:10.1093/jac/dkae235

BibTeX
@article{Ugarte2024,
  author = {Ugarte, Ainoa and De La Mora, Lorena and De Lazzari, Elisa and Chivite, Iván and Fernández, Emma and Inciarte, Alexy and Laguno, Montserrat and Ambrosioni, Juan and Solbes, Estela and Berrocal, Leire and González-Cordón, Ana and Martínez-Rebollar, María and Foncillas, Alberto and Calvo, Júlia and Blanco, José Luis and Martínez, Esteban and Mallolas, Josep and Torres, Berta},
  title = {Rapid initiation of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy in HIV infection. A prospective study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {9},
  pages = {2343--2353},
  doi = {10.1093/jac/dkae235}
}
Kostenlos starten →